PubMed Health⌕ Search

PubMed · 209539

[Progress in clinical oncology 1978].

Abstract

A short survey of recent progress in the diagnosis and pharmacotherapy of neoplastic diseases is conducted, with special mention of measurement of hormone receptors, needle biopsy, tactics and strategy of drug therapy, and new drugs. The importance of several forms of cooperation is stressed: cooperation between doctor and patient, between hospital physician and town physician, interdisciplinary cooperation, and cooperative clinical studies. Adjuvant chemotherapy and immunotherapy are new methods under study. The problems arising in the wake of progress in medical oncology and the ever increasing use of chemotherapy are loss of individual initiative in physicians working with protocols, and prohibitive costs are diagnostic and therapeutic procedures become more sophisticated.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

G Martz. 1978-08-12. [Progress in clinical oncology 1978].. https://pubmed.ncbi.nlm.nih.gov/209539/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

[Revision of the recommendations of the Commission on Pharmacotherapy of the German Society for Rheumatology. Comment on the use of mycophenolic acid for systemic lupus erythematosus].

According to the NIH scheme, the "evidence based medicine" standard in the treatment of severe proliferative lupus-nephritis is cyclophosphamide in combination with steroids. Undesired effects, therapy resistance, and deficient long-term effects underscore the necessity for the development of alternative therapies for the treatment of organ involvement. Mycophenolate mofetil (MMF) possesses the potential to decisively improve the therapeutic possibilities for systemic lupus erythematosus (SLE). On the basis of the available data, MMF represents an alternative to the current standard therapies for severe lupus-nephritises and shows less toxicity. MMF is also effective in patients with other manifestations refractory to conventional therapy. Questions remain unanswered on the optimal dosage and possible reduction in cases of remission. In addition, the duration of maintenance therapy is unclear. Therefore, large, prospective, randomized clinical studies in the treatment of lupus-nephritis with a sufficiently long follow-up phase are underway.

Drug Therapy, Combination↗